BIC22 takeaways
20/09/22 -"During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with ..."
Pages
69
Language
English
Published on
20/09/22
You may also be interested by these reports :
20/11/26
Sanofi’s ‘media-reported’ big acquisitive move can be a credible solution to growth concerns after lynchpin Dupixent loses exclusivity starting in ...
18/11/26
Leaving aside the mid-term profitability outlook downgrade in 2024, Lundbeck has often exceeded expectations with its operational delivery in the ...
17/11/26
In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, ...
17/11/26
The factors discussed in the justification for DCF valuation have also prompted an upgrade to our NAV valuation. As a result, the target price resets ...